{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:58:14Z","timestamp":1792479494293,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1053\/j.seminoncol.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T20:03:39Z","timestamp":1523563419000},"page":"377-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Proteasome inhibitors: structure and function"],"prefix":"10.1053","volume":"44","author":[{"given":"Ana T.","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.01.004_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2018.01.004_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib5","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-\u03baB as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib7","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib8","doi-asserted-by":"crossref","first-page":"21648","DOI":"10.1074\/jbc.M001083200","article-title":"Ubiquitin-mediated degradation of the proapoptotic active form of bid: a functional consequence on apoptosis induction","volume":"275","author":"Breitschopf","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib9","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.4049\/jimmunol.166.5.3130","article-title":"Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells","volume":"166","author":"Marshansky","year":"2001","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/bjc.1995.197","article-title":"Assay of matrix metalloproteinase type 8 and 9 by ELISA in human breast cancer","volume":"71","author":"Duffy","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib12","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1038\/onc.2009.46","article-title":"Noxa: at the tip of the balance between life and death","volume":"27","author":"Ploner","year":"2009","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib13","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ajpath.2010.11.010","article-title":"Proteasome inhibitors induce p53-independent apoptosis in human cancer cells","volume":"178","author":"Pandit","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib15","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/emboj\/cdg227","article-title":"For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin\u2013proteasome connection","volume":"22","author":"Kostova","year":"2003","journal-title":"EMBO J"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib17","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib18","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib19","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib20","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.14113","article-title":"Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients","volume":"174","author":"Levin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13323","article-title":"Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study","volume":"169","author":"Swords","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.004_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Molec Cell Proteom"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417302026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417302026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T07:22:58Z","timestamp":1529565778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417302026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0093775417302026"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome inhibitors: structure and function","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}